News

Pfizer Advances Bold Vision for Future of Cancer Care at the ASCO 2025 Annual Meeting
Pfizer Inc. (NYSE: PFE) will showcase data across its portfolio of potential breakthrough cancer medicines at the 2025 ...
Pfizer to have two oral presentations featured in ASCO pre-meeting briefing
Pfizer (PFE) will showcase data across its portfolio of potential breakthrough cancer medicines at the 2025 American ...
Mirage News1d
Pfizer Unveils Bold Cancer Care Vision at ASCO 2025
Pfizer Inc. (NYSE: PFE) will showcase data across its portfolio of potential breakthrough cancer medicines at the 2025 American Society of Clinical ...
Zacks Investment Research on MSN2d
Pfizer Stock Before Q1 Earnings Release: To Buy or Not to Buy?
Pfizer PFE will report its first-quarter earnings on April 29, before market open. The Zacks Consensus Estimate for sales and ...
pharmaphorum3d
NICE says yes to Braftovi combination for colorectal cancer
BEACON CRC also included another three drug arm – Braftovi, Erbitux, and MEK inhibitor Mektovi (binimetinib) from Array Biopharma (now part of Pfizer). That wasn’t able to improve survival any ...
pharmaphorum2d
Pfizer’s new cancer unit sees eight new blockbusters by 2030
Pfizer’s efforts will span small molecule ... for breast cancer – and the BREAKWATER study of BRAF inhibitor Braftovi (encorafenib) as first-line therapy for BRAF-mutated metastatic colorectal ...
Morningstar2d
Pfizer Advances Bold Vision for Future of Cancer Care at the ASCO 2025 Annual Meeting
Pfizer Inc. (NYSE: PFE) will showcase data across its portfolio of potential breakthrough cancer medicines at the 2025 American Society of Clinical Oncology (ASCO®) Annual Meeting, taking place ...